Clinical trials: NSCLC, Stage I
EGFR Mutation Positive Advanced Non Small Cell Lung Cancer
Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer
This is the first time in patient study to assess the safety, tolerability and preliminary efficacy of AZD3759 in patients with advanced Non Small Cell Lung Cancer (NSCLC) In this study, patients with Leptomeningeal Metastasis…
- Trial name
- BLOOM (NCT02228369)
- Testing
- AZD3759, AZD9291
- Where
- 10 sites in United States, Australia and 2 more
- Volunteers
- 108 people
- Sponsor
- AstraZeneca
Non-Small-Cell Lung Carcinoma
Safety Study of Individualised Radiation Dose Determination for Lung Cancer Patients.
Radiotherapy is treatment of choice for inoperable lung cancer. Research has shown that the local control rate is low and the radiation often causes pneumonitis and/or esophagitis.
- Trial name
- NCT00181545
- Testing
- escalation of dose (radiotherapy treatment)
- Where
- Netherlands
- Volunteers
- 30 people
- Sponsor
- Maastricht Radiation Oncology
Non-Small Cell Lung Cancer
Trial of ABI-007 Administered Weekly in Chemotherapy Naive Patients With Advanced Non-Small Cell Lung Cancer
The anticancer agent paclitaxel (Taxol for Injection Concentrate, Bristol-Meyers Squibb) has a broad spectrum of activity against several human cancers including carcinomas of ovary, breast, lung, esophagus and head and neck…
- Trial name
- NCT00073723
- Testing
- ABI-007
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Celgene Corporation
Anxiety Disorder, Depression
Combination Chemotherapy Plus Fluoxetine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
This trial is designed to test the efficacy of fluoxetine to improve patient's quality of life during chemotherapy. An innovative application of a selective serotonin reuptake inhibitor may modulate the effects of fatigue…
- Conditions
- Anxiety Disorder, Depression, Fatigue, Lung Cancer
- Trial name
- NCT00005850
- Testing
- cisplatin, fluoxetine, gemcitabine hydrochloride
- Where
- 43 sites in United States, Puerto Rico
- Volunteers
- 21 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Lung Cancer, Non Small Cell Lung Cancer
Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
The purpose of this study is to find out what effects (good and/or bad) Pirfenidone combined with standard first-line chemotherapy will have on you and non-small cell lung cancer (NSCLC).
- Conditions
- Lung Cancer, Non Small Cell Lung Cancer, Advanced Cancer, Metastatic Lung Cancer
- Trial name
- NCT03177291
- Testing
- Pirfenidone, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Adenocarcinoma of the Lung, Bronchoalveolar Cell Lung Cancer
Erlotinib and Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Inoperable Stage III Non-Small Cell Lung Cancer
Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Conditions
- Adenocarcinoma of the Lung, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer, Squamous Cell Lung Cancer
- Trial name
- NCT00042835
- Testing
- cisplatin, etoposide, erlotinib hydrochloride
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- National Cancer Institute (NCI)
Non-Small-Cell Lung Carcinoma
Concurrent Helical Tomotherapy With Chemotherapy in Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)
This non-randomized Phase I/II study is designed to determine the maximum tolerated dose (MTD) of thoracic radiotherapy and concurrent chemotherapy with cisplatin and docetaxel in patients with LA-NSCLC.
- Trial name
- NCT00379717
- Testing
- Cisplatinum, Docetaxel, Tomotherapy
- Where
- Belgium
- Volunteers
- 30 people
- Sponsor
- Universitair Ziekenhuis Brussel
Solid Tumor, Adult
FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
This is a Phase 1 dose-finding study of FT538 in combination with monoclonal antibodies.
- Trial name
- NCT05069935
- Testing
- FT538, Cyclophosphamide, Fludarabine
- Where
- 4 sites in United States
- Volunteers
- 16 people
- Sponsor
- Fate Therapeutics
Stage IV Non-small Cell Lung Cancer
Evaluation of Safety and Efficacy of DCVAC/LuCa (Immunotherapy of Lung Cancer) in Patients With Metastatic Lung Cancer
The purpose of the study is to compare efficacy of DCVAC/LuCa + chemotherapy +/- immune enhancers vs. chemotherapy alone in patients with stage IV NSCLC, as measured by progression free survival (PFS).
- Trial name
- NCT02470468
- Testing
- DCVAC add on to SOC, DCVAC and immune enhancers add on to SOC, Standard of Care Chemotherapy
- Where
- 18 sites in Czechia, Slovakia
- Volunteers
- 105 people
- Sponsor
- SOTIO a.s.
Bladder Cancer, Breast Cancer
LMB-9 Immunotoxin in Treating Patients With Advanced Solid Tumors
RATIONALE: The LMB-9 immunotoxin may be able to locate tumor cells and kill them without harming normal cells. This may be an effective treatment for advanced solid tumors.
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Esophageal Cancer
- Trial name
- NCT00019435
- Testing
- LMB-9 immunotoxin
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Non-small Cell Lung Cancer
Neoadjuvant Immunotherapy With Chemotherapy for Stage I-IIIB Non-Small Cell Lung Cancer Patients
A phase II, single-arm, open-label study that assesses feasibility, safety and efficacy of combined neoadjuvant chemotherapy and immunotherapy with PD-(L)1 inhibitor in stage I-IIIB NSCLC adult patients followed by adjuvant…
- Trial name
- NCT04941417
- Testing
- PD-1 inhibitor
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking Union Medical College
Lung Cancer
Radical Lung Radiotherapy Plus Nelfinavir
The aim of this clinical trial is to test whether the drug nelfinavir, which can increase the effectiveness of radiotherapy, can be given safely at the same time as a full dose of radiotherapy for lung cancer.
- Trial name
- NelfLung (NCT01447589)
- Testing
- nelfinavir, Radical Radiotherapy
- Where
- United Kingdom
- Sponsor
- Oxford University Hospitals NHS Trust
Advanced Solid Tumor, Cutaneous Tumor
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
This is a Phase 1, multicenter, open-label dose escalation study to determine the safety and tolerability of intratumoral (IT) injection of tolododekin alfa (ANK-101) in participants with advanced solid tumors who have progressed…
- Conditions
- Advanced Solid Tumor, Cutaneous Tumor, Subcutaneous Tumor, Malignant Solid Tumor
- Trial name
- ANCHOR (NCT06171750)
- Testing
- tolododekin alfa, Cemiplimab
- Where
- 5 sites in United States, Canada
- Volunteers
- 97 people
- Sponsor
- Ankyra Therapeutics, Inc
Lung Cancer
Vaccine Therapy in Treating Patients Who Are Undergoing Surgery for Stage IB, Stage II, or Stage IIIA Non-Small Cell Lung Cancer
RATIONALE: Vaccines made from a person's tumor cells and white blood cells may make the body build an effective immune response to kill tumor cells.
- Trial name
- NCT00098917
- Testing
- autologous tumor cell vaccine, therapeutic autologous dendritic cells, adjuvant therapy
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma
Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor
This phase I trial studies the safety, side effects and best dose of necitumumab when given together with osimertinib in treating patients with EGFR-mutant non-small cell lung cancer that is stage IV or has come back after a…
- Conditions
- Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
- Trial name
- NCT02496663
- Testing
- Biospecimen Collection, Computed Tomography, Echocardiography Test
- Where
- 15 sites in United States
- Volunteers
- 138 people
- Sponsor
- National Cancer Institute (NCI)
Non-Small Cell Lung Cancer, Pancreatic Cancer
A Study of NBF-006 in Non-Small Cell Lung, Pancreatic, or Colorectal Cancer
This is an open-label, non-controlled study conducted in two parts - Part A (dose escalation) followed by Part B (dose expansion).
- Conditions
- Non-Small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer
- Trial name
- NCT03819387
- Testing
- NBF-006
- Where
- 9 sites in United States
- Volunteers
- 49 people
- Sponsor
- Nitto BioPharma, Inc.
Inoperable Stage I/II Non-small Cell Lung Cancer
A Phase I/II Trial of Stereotactic Body Radiation Therapy
The purpose of this study is to use SBRT in patients with early stage lung cancer and find out what effects (good and bad) SBRT has on their cancer.
- Trial name
- SBRT (NCT00591838)
- Testing
- Stereotactic Body Radiation Therapy (SBRT)
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- Washington University School of Medicine
Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Recurrent
Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung Cancer
This phase I/II trial studies the side effects and the best dose of MLN8237 when given together with erlotinib hydrochloride and to see how well it works in treating patients with recurrent locally advanced or metastatic…
- Trial name
- NCT01471964
- Testing
- MLN8237 and Erlotinib
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Fox Chase Cancer Center
NSCLC, EGF-R Positive Non-Small Cell Lung Cancer
Adjuvant Targeted-therapy for Patients With Resected High-risk EGFR-mutant Stage IB-IIA Non-small Cell Lung Carcinoma
This is a single-armed study designed to evaluate the safety and efficacy of adjuvant targeted-therapy in patients with epidermal growth factor receptor mutation positive stage IB-IIA non-small cell lung carcinoma and high-risk…
- Trial name
- ATHEM (NCT05165355)
- Testing
- Furmonertinib
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Tongji University
Non-Small Cell Lung Cancer
A Phase I/II Open-Label, Non-Randomized Dose Escalation Study of Immunoconjugate L-DOS47
The primary purpose of this research study is to evaluate how safe, how well tolerated and how effective a range of doses of L-DOS47 in patients with non-squamous non-small cell lung cancer when given as a monotherapy.
- Trial name
- NCT02340208
- Testing
- L-DOS47
- Where
- 5 sites in Poland
- Volunteers
- 76 people
- Sponsor
- Helix BioPharma Corporation